The multifaceted anti-cancer effects of BRAF-inhibitors.
BRAF
BRAF-inhibitors
CXCL8
chemokines
tumor microenvironment
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
22
07
2019
accepted:
19
10
2019
entrez:
26
11
2019
pubmed:
26
11
2019
medline:
26
11
2019
Statut:
epublish
Résumé
The BRAF gene is commonly involved in normal processes of cell growth and differentiation. The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of the ERK/MAPK-signal cascade. In particular, BRAFV600E mutation is found in those melanoma or thyroid cancer refractory to the common therapy and with a more aggressive phenotype. BRAF V600E was found to influence the composition of the so-called tumour microenvironment modulating both solid (immune-cell infiltration) and soluble (chemokines) mediators, which balance characterize the ultimate behaviour of the tumour, making it more or less aggressive. In particular, the presence of BRAFV600E mutation would be associated with a change of this balance to a more aggressive phenotype of the tumour and a worse prognosis. The investigation of the possible modulation of those components of tumour microenvironment is nowadays object of several studies as a new potential target therapy in those more complicated cases. At present several clinical trials both in melanoma and thyroid cancer are using BRAF-inhibitors with encouraging results, which are derived also from numerous
Identifiants
pubmed: 31762942
doi: 10.18632/oncotarget.27304
pii: 27304
pmc: PMC6859927
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6623-6640Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors have nothing to disclose.
Références
Semin Cancer Biol. 2012 Feb;22(1):33-40
pubmed: 22210179
Cancer Res. 2017 Apr 1;77(7):1599-1610
pubmed: 28202513
Ther Adv Med Oncol. 2019 Jun 18;11:1758835919856494
pubmed: 31244912
Cancer Res. 1992 Jan 15;52(2):464-9
pubmed: 1728417
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Oncoimmunology. 2013 Aug 1;2(8):e25218
pubmed: 24167759
Semin Immunol. 2003 Feb;15(1):49-55
pubmed: 12495640
J Immunol. 2014 Mar 1;192(5):2505-13
pubmed: 24489105
Endocr Relat Cancer. 2019 Aug;26(8):R465-R478
pubmed: 31146261
Cancer Res. 2018 Sep 1;78(17):5038-5049
pubmed: 30026331
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Clin Cancer Res. 2012 Mar 1;18(5):1386-94
pubmed: 22156613
Cancer Res. 2016 Mar 15;76(6):1476-84
pubmed: 26825172
Oncoimmunology. 2015 Aug 17;5(7):e1052212
pubmed: 27622011
Cancer Lett. 2016 Oct 1;380(2):577-585
pubmed: 26189429
Endocr Relat Cancer. 2013 Feb 18;20(1):103-10
pubmed: 23193072
Endocr Relat Cancer. 2008 Mar;15(1):191-205
pubmed: 18310287
Clin Cancer Res. 2015 Mar 1;21(5):1028-35
pubmed: 25549723
Nat Genet. 2003 Jan;33(1):19-20
pubmed: 12447372
Front Endocrinol (Lausanne). 2018 Jun 21;9:314
pubmed: 29977225
Br J Cancer. 2018 Nov;119(10):1223-1232
pubmed: 30327563
Oncotarget. 2019 Jan 11;10(4):551-557
pubmed: 30728904
Br J Cancer. 2006 Sep 4;95(5):581-6
pubmed: 16880785
Clin Cancer Res. 2013 Feb 1;19(3):598-609
pubmed: 23095323
Gut. 2012 Mar;61(3):427-38
pubmed: 21930732
Cytokine. 2017 Sep;97:73-79
pubmed: 28582647
Nature. 2010 Dec 16;468(7326):973-7
pubmed: 21107323
J Clin Oncol. 2001 Jan 15;19(2):577-83
pubmed: 11208853
Lancet Oncol. 2016 Sep;17(9):1272-82
pubmed: 27460442
Endocr Relat Cancer. 2019 Jun;26(6):601-614
pubmed: 30965283
Cancer Immunol Immunother. 2013 Apr;62(4):811-22
pubmed: 23306863
J Thorac Dis. 2019 Jan;11(Suppl 1):S81-S88
pubmed: 30775031
Nat Rev Clin Oncol. 2014 Jul;11(7):385-400
pubmed: 24840079
Cancers (Basel). 2018 Dec 05;10(12):
pubmed: 30563160
J Clin Oncol. 2011 Aug 1;29(22):3085-96
pubmed: 21383288
Neoplasia. 2019 Jan;21(1):52-60
pubmed: 30504064
J Clin Invest. 2013 Mar;123(3):1371-81
pubmed: 23454771
Nature. 2011 Nov 23;480(7377):387-90
pubmed: 22113612
Oncoimmunology. 2013 Jan 1;2(1):e22890
pubmed: 23483066
Clin Cancer Res. 2014 Nov 15;20(22):5697-707
pubmed: 25224278
Oncotarget. 2018 Dec 25;9(101):37589-37607
pubmed: 30680072
Endocr Rev. 2007 Aug;28(5):492-520
pubmed: 17475924
Cytokine Growth Factor Rev. 2010 Feb;21(1):27-39
pubmed: 20004131
Clin Cancer Res. 2012 Oct 1;18(19):5329-40
pubmed: 22850568
J Interferon Cytokine Res. 2013 Sep;33(9):508-13
pubmed: 23675779
Nature. 2017 Oct 5;550(7674):133-136
pubmed: 28953887
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54
pubmed: 20498063
Clin Cancer Res. 2011 Aug 15;17(16):5247-56
pubmed: 21659461
Pharmacol Res. 2018 Sep;135:239-258
pubmed: 30118796
Cytokine Growth Factor Rev. 2013 Dec;24(6):539-46
pubmed: 24011840
Oncologist. 2011;16(3):296-309
pubmed: 21355020
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Clin Pharmacol Ther. 2010 Apr;87(4):401-6
pubmed: 20200512
J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47
pubmed: 24297791
J Clin Endocrinol Metab. 2010 Jan;95(1):450-5
pubmed: 19880792
Nat Commun. 2019 Jun 24;10(1):2764
pubmed: 31235699
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Br J Cancer. 2017 Apr 11;116(8):1065-1076
pubmed: 28301874
Endocrine. 2016 Oct;54(1):123-128
pubmed: 26450713
Oncotarget. 2018 Jun 19;9(47):28294-28308
pubmed: 29983861
Clin Cancer Res. 2011 Dec 15;17(24):7511-7
pubmed: 21900390
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Endocrinol Invest. 2018 Nov;41(11):1275-1282
pubmed: 29546654
J Exp Med. 2006 Jul 10;203(7):1651-6
pubmed: 16801397
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Oncoimmunology. 2013 Oct 1;2(10):e26615
pubmed: 24251082
Melanoma Res. 2014 Dec;24(6):621-5
pubmed: 25211166
Nature. 2010 Dec 16;468(7326):968-72
pubmed: 21107320
Int J Cancer. 2002 Feb 10;97(5):608-14
pubmed: 11807785
J Clin Endocrinol Metab. 1992 Jul;75(1):328-30
pubmed: 1619027
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6
pubmed: 18287029
J Clin Endocrinol Metab. 2015 Mar;100(3):E427-32
pubmed: 25590211
Cancer Invest. 2010 Aug;28(7):765-73
pubmed: 20569070
J Clin Invest. 2005 Jan;115(1):94-101
pubmed: 15630448
Pathology. 2015 Oct;47(6):557-63
pubmed: 26308130
J Leukoc Biol. 2006 Apr;79(4):639-51
pubmed: 16478915
Oncoimmunology. 2013 Jul 1;2(7):e25474
pubmed: 24073384
Melanoma Res. 2006 Aug;16(4):267-73
pubmed: 16845322
Mediators Inflamm. 2016;2016:8512417
pubmed: 27555670
Endocr Relat Cancer. 2014 Apr 28;21(3):R85-R103
pubmed: 24302667
Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91
pubmed: 11544106
Endocr Connect. 2019 Jul;8(7):988-996
pubmed: 31252408
Sci Rep. 2019 Mar 13;9(1):4390
pubmed: 30867499
Nature. 2014 Apr 3;508(7494):118-22
pubmed: 24670642
Ann Surg. 2015 Sep;262(3):519-25; discussion 524-5
pubmed: 26258321
Curr Opin Genet Dev. 2007 Feb;17(1):31-9
pubmed: 17208430
Nat Commun. 2012 Mar 06;3:724
pubmed: 22395615
Curr Opin Pharmacol. 2019 Jun;46:116-121
pubmed: 31261023
Drugs. 2018 Apr;78(5):549-566
pubmed: 29488071
Oncotarget. 2019 Nov 05;10(60):6432-6443
pubmed: 31741708
Endocr Relat Cancer. 2018 Jan;25(1):99-109
pubmed: 29269566
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Thyroid. 2015 Jan;25(1):71-7
pubmed: 25285888
J Clin Endocrinol Metab. 2013 Jan;98(1):308-13
pubmed: 23118425
Nat Med. 2019 Jun;25(6):929-935
pubmed: 31171876
Oncotarget. 2016 Jan 26;7(4):4428-41
pubmed: 26684239
Mod Pathol. 2012 Jan;25(1):46-55
pubmed: 21909080
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Cancer Treat Rev. 2017 Nov;60:24-31
pubmed: 28866366
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Oncotarget. 2013 Dec;4(12):2171-85
pubmed: 24259307
Ann Oncol. 2017 Nov 1;28(11):2648-2657
pubmed: 29045527
Oncotarget. 2014 Jun 30;5(12):3996-4010
pubmed: 24994118
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859
Exp Cell Res. 2011 Mar 10;317(5):664-73
pubmed: 21134366
Cancer Res. 2014 Jun 15;74(12):3205-17
pubmed: 24736544